Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) | |
US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) | |
US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 07 June, 2006
Treatment: Treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar i disorder, adjunctive treatment of major depressive disorder, and treatment of irritability associated with autistic disorder
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8993761 | OTSUKA PHARM CO LTD | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) | |
US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) | |
US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(4 months ago) |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Acute treatment of manic and mixed episodes associated with bipolar i disorder; Adjunctive treatment of major depressive disorder (mdd); Treatment of schizophrenia
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7420057 | SPROUT PHARMS | Stable polymorph of flibanserin |
Aug, 2022
(5 months ago) |
Drugs and Companies using FLIBANSERIN ingredient
Market Authorisation Date: 18 August, 2015
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6828339 | SYNTHON PHARMS | Amlodipine salt forms and processes for preparing them |
Nov, 2022
(2 months ago) |
Drugs and Companies using AMLODIPINE BESYLATE ingredient
Market Authorisation Date: 27 September, 2007
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6740669 | EISAI INC | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Nov, 2022
(2 months ago) |
Drugs and Companies using RUFINAMIDE ingredient
Market Authorisation Date: 03 March, 2011
Treatment: NA
Dosage: SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6441168 | BAYER HLTHCARE | Stable crystalline salts of 5-methyltetrahydrofolic acid |
Jul, 2022
(6 months ago) |
Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient
Market Authorisation Date: 24 September, 2010
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7132416 | ALBIREO | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia |
Sep, 2022
(4 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 20, 2026 |
Orphan Drug Exclusivity (ODE) | Jul 20, 2028 |
Drugs and Companies using ODEVIXIBAT ingredient
NCE-1 date: July, 2025
Market Authorisation Date: 20 July, 2021
Treatment: NA
Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE42353 | GENZYME CORP | Quinazoline derivatives and pharmaceutical compositions containing them |
Jun, 2022
(7 months ago) |
Drugs and Companies using VANDETANIB ingredient
Market Authorisation Date: 06 April, 2011
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6916802 | GENZYME CORP | Amino ceramide-like compounds and therapeutic methods of use |
Apr, 2022
(9 months ago) |
Drugs and Companies using ELIGLUSTAT TARTRATE ingredient
Market Authorisation Date: 19 August, 2014
Treatment: Treatment of gaucher disease type 1
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6890927 | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
May, 2022
(8 months ago) | |
US7265119 | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Aug, 2022
(5 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Feb 22, 2022 |
Pediatric Exclusivity (PED) | Aug 22, 2022 |
Drugs and Companies using VARENICLINE TARTRATE ingredient
Market Authorisation Date: 10 May, 2006
Treatment: Aid to smoking cessation
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7642258 | ALLERGAN | Combination of brimonidine and timolol for topical ophthalmic use |
Apr, 2022
(9 months ago) |
Drugs and Companies using BRIMONIDINE TARTRATE; TIMOLOL MALEATE ingredient
Market Authorisation Date: 30 October, 2007
Treatment: Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop
Dosage: SOLUTION/DROPS;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10195159 | GW RES LTD | Processes and apparatus for extraction of active substances and enriched extracts from natural products |
May, 2022
(8 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 28, 2023 |
Orphan Drug Exclusivity (ODE) | Jul 31, 2027 |
New Patient Population (NPP) | Jul 31, 2023 |
Drugs and Companies using CANNABIDIOL ingredient
NCE-1 date: September, 2022
Market Authorisation Date: 28 September, 2018
Treatment: NA
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6028071 | ACROTECH | Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors |
Jul, 2022
(6 months ago) |
Drugs and Companies using PRALATREXATE ingredient
Market Authorisation Date: 24 September, 2009
Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6500829 | ACROTECH | Substantially pure diastereoisomers of tetrahydrofolate derivatives |
Mar, 2022
(10 months ago) |
Drugs and Companies using LEVOLEUCOVORIN CALCIUM ingredient
Market Authorisation Date: 07 March, 2008
Treatment: NA
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8546143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of a target gene |
Jan, 2022
(1 year, 21 days ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 20, 2024 |
Orphan Drug Exclusivity (ODE) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: November, 2023
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US5856529 | VANDA PHARMS INC | Benzofuran and dihydrobenzofuran melatonergic agents |
Dec, 2022
(a month ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Dec 1, 2023 |
Orphan Drug Exclusivity (ODE) | Dec 1, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 31 January, 2014
Treatment: Treatment of non-24 hour sleep-wake disorder by administering tasimelteon; Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US5856529 | VANDA PHARMS INC | Benzofuran and dihydrobenzofuran melatonergic agents |
Dec, 2022
(a month ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Dec 1, 2023 |
Orphan Drug Exclusivity (ODE) | Dec 1, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon
Dosage: SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8048917 | AZURITY | Prodrugs of GABA analogs, compositions and uses thereof |
Nov, 2022
(2 months ago) |
Drugs and Companies using GABAPENTIN ENACARBIL ingredient
Market Authorisation Date: 06 April, 2011
Treatment: Management of postherpetic neuralgia (phn) in adults
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(6 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Aug 12, 2022 |
Pediatric Exclusivity (PED) | Jun 4, 2024 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 30 March, 2007
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(6 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Dec 4, 2023 |
Pediatric Exclusivity (PED) | Jun 4, 2024 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 02 February, 2012
Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(6 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Dec 4, 2023 |
Pediatric Exclusivity (PED) | Feb 12, 2023 |
Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 16 October, 2006
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(6 months ago) |
Drugs and Companies using SIMVASTATIN; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9074213 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Mar, 2022
(10 months ago) | |
US8546143 | NOVARTIS | Compositions and methods for inhibiting expression of a target gene |
Apr, 2022
(9 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: December, 2025
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6916941 | ALLERGAN | Crystalline composition containing escitalopram |
Aug, 2022
(5 months ago) |
Drugs and Companies using ESCITALOPRAM OXALATE ingredient
Market Authorisation Date: 14 August, 2002
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6403567 | ASTELLAS | N-pyrazole A2A adenosine receptor agonists |
Apr, 2022
(9 months ago) |
Drugs and Companies using REGADENOSON ingredient
Market Authorisation Date: 10 April, 2008
Treatment: Method for stimulating coronary vasodilation for purposes of imaging the heart
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6204257 | EISAI INC | Water soluble prodrugs of hindered alcohols |
Jul, 2022
(6 months ago) |
Drugs and Companies using FOSPROPOFOL DISODIUM ingredient
Market Authorisation Date: 12 December, 2008
Treatment: Sedative-hypnotic agent indicated for monitored anesthesia care (mac) sedation
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7151102 | ASTRAZENECA | Phthalazinone derivatives |
Apr, 2022
(9 months ago) |
Drugs and Companies using OLAPARIB ingredient
Market Authorisation Date: 19 December, 2014
Treatment: NA
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6861409 | NOVO | Growth hormone secretagogues |
Aug, 2022
(5 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 20, 2024 |
New Chemical Entity Exclusivity (NCE) | Dec 20, 2022 |
Drugs and Companies using MACIMORELIN ACETATE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 20 December, 2017
Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin
Dosage: FOR SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7662365 | REDHILL | Polymer conjugates of opioid antagonists |
Oct, 2022
(3 months ago) |
Drugs and Companies using NALOXEGOL OXALATE ingredient
Market Authorisation Date: 16 September, 2014
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6346532 | APGDI | Amide derivatives or salts thereof |
Mar, 2022
(10 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Mar 25, 2024 |
Pediatric Exclusivity (PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
Market Authorisation Date: 28 June, 2012
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6346532 | APGDI | Amide derivatives or salts thereof |
Mar, 2022
(10 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Mar 25, 2024 |
Pediatric Exclusivity (PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
Market Authorisation Date: 25 March, 2021
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE39593 | COLLEGIUM PHARM INC | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects |
Aug, 2022
(5 months ago) |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2012
Treatment: Relief of moderate to severe acute pain
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE39593 | COLLEGIUM PHARM INC | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects |
Aug, 2022
(5 months ago) |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 25 August, 2011
Treatment: Management of neuropathic pain associated with diabetic peripheral neuropathy; Relief of moderate to severe chronic pain
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7138390 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Nov, 2022
(2 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | May 27, 2023 |
Drugs and Companies using OBETICHOLIC ACID ingredient
Market Authorisation Date: 27 May, 2016
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6673838 | PF PRISM CV | Succinate salt of O-desmethyl-venlafaxine |
Mar, 2022
(10 months ago) |
Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient
Market Authorisation Date: 29 February, 2008
Treatment: For the approved uses and conditions of use, including depression; Maintenance treatment of major depressive disorder (mdd)
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(2 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 16, 2025 |
Pediatric Exclusivity (PED) | Feb 26, 2022 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date: 20 November, 2008
Treatment: Treatment of idiopathic thrombocytopenic purpura (itp); Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp); Treatment of thrombocytopenia in adult and pediatric patients 6 years and older with chronic immune (idiopathic) thrombocytopenia (itp); Patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7160870 | NOVARTIS | Thrombopoietin mimetics |
Nov, 2022
(2 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 16, 2025 |
Pediatric Exclusivity (PED) | Feb 26, 2022 |
Drugs and Companies using ELTROMBOPAG OLAMINE ingredient
Market Authorisation Date: 24 August, 2015
Treatment: Treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of interferon-based therapy; Treatment of thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (itp)
Dosage: FOR SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6268343 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2022
(5 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Dec 4, 2023 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
Market Authorisation Date: 23 December, 2014
Treatment: Method for chronic weight management by treating obesity
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(6 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 19, 2022 |
M | Sep 17, 2024 |
Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7351834 | BAYER HLTHCARE | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jun, 2022
(7 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 27, 2024 |
Drugs and Companies using REGORAFENIB ingredient
Market Authorisation Date: 27 September, 2012
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6417175 | ALLERGAN | Phosphonocephem derivatives, process for the preparation of the same, and use thereof |
Apr, 2022
(9 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Sep 13, 2022 |
Drugs and Companies using CEFTAROLINE FOSAMIL ingredient
Market Authorisation Date: 29 October, 2010
Treatment: Methods for treating bacterial infections
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6858650 | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jul, 2022
(6 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Jun 17, 2024 |
Pediatric Exclusivity (PED) | Dec 17, 2024 |
Drugs and Companies using FESOTERODINE FUMARATE ingredient
Market Authorisation Date: 31 October, 2008
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7799897 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jun, 2022
(7 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 19, 2022 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: January, 2021
Market Authorisation Date: 19 January, 2017
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6713446 | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jan, 2022
(1 year, 5 days ago) | |
US6958319 | TAKEDA PHARMS USA | Formulation of boronic acid compounds |
Jan, 2022
(1 year, 5 days ago) |
Exclusivity | Exclusivity Expiration |
---|---|
Pediatric Exclusivity (PED) | Apr 8, 2022 |
Drugs and Companies using BORTEZOMIB ingredient
Market Authorisation Date: 13 May, 2003
Treatment: NA
Dosage: INJECTABLE;INTRAVENOUS, SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6268343 | NOVO NORDISK INC | Derivatives of GLP-1 analogs |
Aug, 2022
(5 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jun 17, 2022 |
Pediatric Exclusivity (PED) | Dec 17, 2022 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
Market Authorisation Date: 25 January, 2010
Treatment: A method for improving glycemic control in adults with type 2 diabetes mellitus
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8673921 | ALLERGAN | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(7 months ago) | |
US7834020 | ALLERGAN | Polymorphic forms of 1-′4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(7 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Jan 31, 2023 |
Pediatric Exclusivity (PED) | Jul 31, 2023 |
Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 January, 2011
Treatment: Treatment of major depressive disorder (mdd)
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
USRE38551 | UCB INC | Anticonvulsant enantiomeric amino acid derivatives |
Mar, 2022
(10 months ago) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Nov 16, 2023 |
New Patient Population (NPP) | Oct 14, 2024 |
Drugs and Companies using LACOSAMIDE ingredient
Market Authorisation Date: 20 April, 2010
Treatment: Method of treating partial onset seizures in patients 4 years of age and older; Method of treating, as initial loading dose for monotherapy or adjunctive therapy, partial onset-seizures in a patient with epilepsy aged 17 years or older; Method of use of treating, as an initial loading dose for monotherapy or adjunctive therapy in partial onset seizure patients with epilepsy aged 17 years or older; Method of use for treatment of partial-onset seizures in patients 4 years of age and older; Method of use as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US5886035 | AKORN | Difluoroprostaglandin derivatives and their use |
Dec, 2022
(a month ago) |
Drugs and Companies using TAFLUPROST ingredient
Market Authorisation Date: 10 February, 2012
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
Click on the highlighted region to filter.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US6835809 | NA | Thrombopoietic compounds |
Jan, 2022
(1 year, 11 days ago) |
Ingredients: ROMIPLOSTIM
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US5985320 | NA | Materials and methods for enhancing cellular internalization |
Mar, 2022
(10 months ago) |
Ingredients: TRIPTORELIN ACETATE
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US9546212 | ABBVIE INC. | Methods of administering anti-TNFα antibodies |
Jun, 2022
(7 months ago) | |
US8911737 | ABBVIE INC. | Methods of administering anti-TNFα antibodies |
Jun, 2022
(7 months ago) | |
US8974790 | ABBVIE INC. | Methods of administering anti-TNFα antibodies |
Jun, 2022
(7 months ago) | |
US8992926 | ABBVIE INC. | Methods of administering anti-TNFα antibodies |
Jun, 2022
(7 months ago) |
Ingredients: ADALIMUMAB
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US7138262 | NA | High mannose proteins and methods of making high mannose proteins |
Jul, 2022
(6 months ago) |
Ingredients: VELAGLUCERASE ALFA
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US6828121 | GENENTECH, INC. | Bacterial host strains |
Jul, 2022
(6 months ago) | |
US9688775 | GENENTECH, INC. | System for antibody expression and assembly |
Dec, 2022
(30 days ago) |
Ingredients: RANIBIZUMAB
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US6268343 | NA | Derivatives of GLP-1 analogs |
Aug, 2022
(5 months ago) |
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US7446175 | NA | NA |
Dec, 2022
(a month ago) |
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US6309650 | NA | Attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine |
Dec, 2022
(a month ago) |
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic